Latest news with #EastmanChemical
Yahoo
a day ago
- Business
- Yahoo
Isobutyric Acid Market to Reach USD 356.84 million by 2032
Growing use in sustainable bio-based chemicals drives Isobutyric Acid demand; expanding applications in nutraceutical formulations boost market growth. Austin, June 09, 2025 (GLOBE NEWSWIRE) -- The Isobutyric Acid Market Size was valued at USD 197.35 million in 2024 and is expected to reach USD 356.84 million by 2032, growing at a CAGR of 7.69% over the forecast period of 2025-2032. Expansion of Green Chemistry and Health-Focused Manufacturing Drives the Multifaceted Growth of the Global Isobutyric Acid Industry The Isobutyric Acid market is growing steadily due to its wide use in pharmaceuticals, food flavorings, and chemical intermediates like vitamins and plasticizers. Regulatory backing from the U.S. FDA and the USDA's push for renewable chemicals are boosting confidence. Companies such as BASF and Eastman Chemical are expanding capacities to meet demand. Rising interest in natural ingredients and advances in synthetic production are improving quality and affordability. Biotechnology investments are further driving innovation, ensuring sustained growth across various industrial PDF Sample of Isobutyric Acid Market @ The U.S. Isobutyric Acid Market had the largest market share of 77% in 2024, with a market size of USD 51.63 million. The U.S. Isobutyric Acid market is growing steadily, driven by pharmaceutical industry expansion and consumer preference for health-focused ingredients. FDA's encouragement of bio-based chemicals and companies like DuPont introducing bio-derived Isobutyric Acid derivatives support this growth, bolstered by rising healthcare product innovations. Key Players: Eastman Chemical Company OQ Chemicals GmbH Dow Inc. Evonik Industries AG AFYREN Jiangsu Dynamic Chemical Co., Ltd. Tokyo Chemical Industry Co., Ltd. Weifang Qiyi Chemical Co., Ltd. Shanghai Aladdin Biochemical Technology Co., Ltd. Hubei Jusheng Technology Co., Ltd. Isobutyric Acid Market Report Scope: Report Attributes Details Market Size in 2024 USD 197.35 million Market Size by 2032 USD 356.84 million CAGR CAGR of 7.69% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Drivers • Expansion of Bio-Based Production Facilities Enhances Isobutyric Acid Market Growth.• Rising Demand for Pharmaceutical-Grade Isobutyric Acid Fuels Market Expansion. If You Need Any Customization on Isobutyric Acid Market Report, Inquire Now @ By Type, Synthetic Isobutyric Acid Dominated the Isobutyric Acid Market in 2024 with a 68.5% Market Share. This dominance is due to its cost-efficiency, high purity, and consistent quality, meeting industry standards for pharmaceuticals and chemicals. Its scalable production suits large-volume applications like plasticizers and solvents. Eastman Chemical's Tennessee facility saw a 12% output rise in 2023 to meet growing demand. While renewable Isobutyric Acid is gaining interest, it currently trails due to higher costs and limited scalability. However, investments in bio-fermentation technologies indicate promising future growth for the renewable segment. By End-use, the Pharmaceutical Application dominated the Isobutyric Acid Market in 2024 with a 31.6% Market Share. The dominance is due to Isobutyric Acid's vital role in drug synthesis, including beta-blockers and vitamin E derivatives. FDA approvals and increased R&D have expanded its use, with companies like Pfizer and Johnson & Johnson relying heavily on it. Growing global demand for advanced therapies and personalized medicine drives further growth. While food & flavor and animal feed sectors contribute, they remain secondary due to more specialized applications, reinforcing pharmaceuticals as the primary driver of market dominance. North America dominated the Isobutyric Acid Market in 2024, Holding a 34.2% Market Share. North America leads the Isobutyric Acid market due to its advanced pharmaceutical and chemical industries, strong R&D investments, and strict regulatory standards. U.S. companies like BASF and Eastman Chemical have expanded production to meet rising demand. Government initiatives supporting bio-based chemicals have boosted renewable Isobutyric Acid development. Additionally, top research institutions and biotech firms drive innovation, strengthening the region's leadership in product development and global supply, and securing its position as the leading contributor to the global Isobutyric Acid market. Asia Pacific is the fastest-growing region in the Isobutyric Acid Market in 2024, holding the Highest CAGR of 9.37%. Asia Pacific's growth in the Isobutyric Acid market is driven by rapid industrialization, expanding pharmaceutical production, and increasing consumer awareness. China and India are investing heavily in chemical infrastructure, backed by green chemistry incentives. Rising demand from the food flavoring and personal care sectors further boosts the market. Chinese firms have introduced Isobutyric Acid-infused flavorings, widely used in beverages. Collaborations between Asian manufacturers and Western tech providers are enhancing product quality and efficiency, accelerating regional market Full Research Report @ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Yahoo
3 days ago
- Business
- Yahoo
Ethyl Cyanoacetate Market Projected to Reach USD 217.65 Million by 2032, Driven by Pharmaceutical and Organic Electronics Demand
Surging demand in organic synthesis and increasing usage in specialty chemicals and biodegradable products are propelling growth in the Ethyl Cyanoacetate market. Austin, June 07, 2025 (GLOBE NEWSWIRE) -- The Ethyl Cyanoacetate Market Size was valued at USD 147.00 million in 2024 and is expected to reach USD 217.65 million by 2032, growing at a CAGR of 5.03% over the forecast period of PDF Sample of Ethyl Cyanoacetate Market @ Growing Demand Across Pharmaceuticals and Cosmetics Drives the Expansion of Ethyl Cyanoacetate Applications in Safer Industrial Processes Ethyl cyanoacetate demand is increasing as this intermediate is vital in the synthesis of pharmaceutical drugs and cosmetics. Between 2022 and 2024, its use in active pharmaceutical ingredients is projected to have risen by 12%, reflecting the increase in generic drugs production. In 2023, the American Chemical Society also reported that it was effectively used to improve cosmetics for skin health and anti-aging. Environment regulations in North America and Europe are driving the transition to safer chemical intermediates, which in turn, are amplifying utilization in a wide range of industries. Big producers like Eastman Chemical and BASF have spent, since 2022, increasing capacity in expectation of continued demand. Being widely used in health care, beauty, and industry, ethyl cyanoacetate is becoming a vital ingredient in worldwide manufacturing and product development. The US Ethyl Cyanoacetate Market had the largest market share of 64% in 2024, growing at a CAGR of 4.62% over the forecast period of 2024-2032. The U.S. ethyl cyanoacetate industry is rapidly expanding on account of increasing pharmaceutical and cosmetic production. Companies such as the FDA reported a rate of usage of Ethyl Cyanoacetate as an intermediate in drug and personal care products. DuPont and Ashland, amongst others, are heavily investing in R&D to improve product purity and efficiency, driving market growth. Key Players: Tiande Chemical Holdings Limited Hebei Chengxin Co., Ltd. Tokyo Chemical Industry Co., Ltd. EMCO Dyestuff Pvt. Ltd. Triveni Techno Chem Shandong Xinhua Pharmaceutical Co., Ltd. Tateyama Kasei Co., Ltd. Loba Chemie Pvt. Ltd. Sisco Research Laboratories Pvt. Ltd. Merck KGaA By Grade, the Pharmaceutical Grade Dominated the Ethyl Cyanoacetate Market in 2024 with a 45% Market Share. This is because this active ingredient is a crucial precursor in producing a wide range of active pharmaceutical ingredients (APIs). For it is known, Ethyl Cyanoacetate is widely used in manufacturing cardiovascular and anti-inflammatory agents, according to the US FDA. We are pharmaceutical companies with pharmaceutical-grade Ethyl Cyanoacetate soda, because of its purity, the pharmaceutical industry has high purity and quality are very strict, and safety and efficacy of the products. By Purity, 98% to 99% Dominated the Ethyl Cyanoacetate Market in 2024 with a 56% Market Share. The supremacy is largely because in pharmaceuticals and cosmetics, this range of purity represents an excellent compromise between cost-effectiveness and performance. This grade is used to prepare high-purity fine chemicals, drug intermediates, etc., which require high purity but not ultra-pure conditions. For example, in the cosmetic industry, Ethyl Cyanoacetate of this purity is used in the manufacture of anti-aging and skin rejuvenation products, as cited in recent American Chemical Society articles. There is a preference among industrial users for this aliquot because of quality and consistency, as well. Manufacturers like Eastman Chemical, which are concentrating on streamlining production processes to address purity requirements quickly, help propel the segment. By Function, the Chemical Intermediates Dominated the Ethyl Cyanoacetate Market in 2024 with a 38% Market Share. Their use has continued to expand due to increased use in pharmaceutical and agrochemical preparations. Ethyl Cyanoacetate is a key precursor in the production of herbicides, insecticides and medicinal molecules etc. For instance, BASF's agrochemical segment has increased use of Ethyl Cyanoacetate intermediates for environment-friendly pesticide development, as environmental apprehensions escalate. The sector is also helped by progress in green chemistry, with encouragement for safer intermediate chemicals. All these factors together make chemical intermediates the largest among the functional segments. Buy Full Research Report on Ethyl Cyanoacetate Market 2025-2032 @ North America dominated the Ethyl Cyanoacetate Market in 2024, Holding a 38.5% Market Share. This dominance can be ascribed to the strong presence of the pharmaceutical industry, high healthcare spending, and key chemical producers in the region. The streamlined & revised US drug policy has led to quicker drug approvals, in turn driving the demand for Ethyl Cyanoacetate in API synthesis. Eastman Chemical and DuPont have large manufacturing operations here, providing a dependable supply. In addition, increasing consumer knowledge about the personal care and beauty products that contain Ethyl Cyanoacetate has fueled the demand from the cosmetics industry. These conditions, as a group, solidify North America's position as the leading region. About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Yahoo
30-05-2025
- Business
- Yahoo
Albemarle (ALB) Down 3.1% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Albemarle (ALB). Shares have lost about 3.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Albemarle due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. It turns out, fresh estimates have trended downward during the past month. The consensus estimate has shifted -383.7% due to these changes. Currently, Albemarle has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Albemarle has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Albemarle belongs to the Zacks Chemical - Diversified industry. Another stock from the same industry, Eastman Chemical (EMN), has gained 6.9% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. Eastman Chemical reported revenues of $2.29 billion in the last reported quarter, representing a year-over-year change of -0.9%. EPS of $1.91 for the same period compares with $1.61 a year ago. For the current quarter, Eastman Chemical is expected to post earnings of $1.80 per share, indicating a change of -16.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #4 (Sell) for Eastman Chemical. Also, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB) : Free Stock Analysis Report Eastman Chemical Company (EMN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-03-2025
- Business
- Yahoo
Is There An Opportunity With Eastman Chemical Company's (NYSE:EMN) 26% Undervaluation?
Eastman Chemical's estimated fair value is US$122 based on 2 Stage Free Cash Flow to Equity Eastman Chemical is estimated to be 26% undervalued based on current share price of US$91.16 Our fair value estimate is 6.6% higher than Eastman Chemical's analyst price target of US$115 Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Eastman Chemical Company (NYSE:EMN) as an investment opportunity by taking the forecast future cash flows of the company and discounting them back to today's value. This will be done using the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. See our latest analysis for Eastman Chemical We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF ($, Millions) US$633.2m US$710.7m US$742.4m US$769.4m US$795.3m US$820.6m US$845.7m US$870.7m US$896.0m US$921.5m Growth Rate Estimate Source Analyst x7 Analyst x7 Analyst x4 Est @ 3.64% Est @ 3.37% Est @ 3.18% Est @ 3.05% Est @ 2.96% Est @ 2.90% Est @ 2.85% Present Value ($, Millions) Discounted @ 7.8% US$587 US$611 US$592 US$569 US$546 US$522 US$499 US$477 US$455 US$434 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$5.3b After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.8%. We discount the terminal cash flows to today's value at a cost of equity of 7.8%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$922m× (1 + 2.8%) ÷ (7.8%– 2.8%) = US$19b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$19b÷ ( 1 + 7.8%)10= US$8.8b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$14b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of US$91.2, the company appears a touch undervalued at a 26% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Eastman Chemical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.8%, which is based on a levered beta of 1.170. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Strength Debt is well covered by earnings and cashflows. Dividends are covered by earnings and cash flows. Weakness Earnings growth over the past year underperformed the Chemicals industry. Dividend is low compared to the top 25% of dividend payers in the Chemicals market. Opportunity Annual earnings are forecast to grow for the next 3 years. Good value based on P/E ratio and estimated fair value. Threat Annual earnings are forecast to grow slower than the American market. Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Why is the intrinsic value higher than the current share price? For Eastman Chemical, we've compiled three fundamental elements you should further research: Risks: For example, we've discovered 1 warning sign for Eastman Chemical that you should be aware of before investing here. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for EMN's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
17-02-2025
- Business
- Yahoo
Those who invested in Eastman Chemical (NYSE:EMN) five years ago are up 69%
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. But Eastman Chemical Company (NYSE:EMN) has fallen short of that second goal, with a share price rise of 42% over five years, which is below the market return. Over the last twelve months the stock price has risen a very respectable 19%. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. See our latest analysis for Eastman Chemical To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Eastman Chemical achieved compound earnings per share (EPS) growth of 7.3% per year. That makes the EPS growth particularly close to the yearly share price growth of 7%. Therefore one could conclude that sentiment towards the shares hasn't morphed very much. Indeed, it would appear the share price is reacting to the EPS. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It might be well worthwhile taking a look at our free report on Eastman Chemical's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Eastman Chemical, it has a TSR of 69% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Eastman Chemical's TSR for the year was broadly in line with the market average, at 23%. Most would be happy with a gain, and it helps that the year's return is actually better than the average return over five years, which was 11%. It is possible that management foresight will bring growth well into the future, even if the share price slows down. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 1 warning sign for Eastman Chemical that you should be aware of. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
